Stockreport

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]

Jade Biosciences, Inc.  (JBIO) 
PDF with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expec [Read more]